December 2, 2020 @ 2:00 pm – 3:00 pm
Learn new Hainan RWD program to use NMPA unapproved devices in China directly from the authorities. Find out how to cut years to months for initial clinical use in real world setting with China Hainan Real-World Data/Study (RWD/S) Pilot Program. This new policy allows overseas medical devices, IVDs and drugs that have NOT been approved in China to be sold and used in real world clinical settings in Lecheng Hainan province. This is especially significant for overseas manufacturers with high-value and innovative devices that normally require clinical trials by China NMPA. In this webinar, you will get fantastic value and receive guidance of the Hainan RWD/S program from Hainan officials. Check out this webinar to see whether and how you can benefit from the program to accelerate your China commercialization in months with Hainan program. Key Highlight:
- What is the latest scope/requirements for Hainan urgent use and RWD/S Pilot program?
- How to leverage the RWS evidence to supplement the NMPA regular submission?
- Learn about the latest practices and case studies of Hainan RWD program
- How you can benefit from the program to accelerate your China commercialization with RWD/S
Details
- Date:
- December 2, 2020
- Time:
-
2:00 pm – 3:00 pm
- Event Category:
- Webinar